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Abstract
Introduction: Acute respiratory distress syndrome (ARDS) is a syndrome characterized by diffuse pulmonary edema
and severe hypoxemia that usually occurs after an injury such as sepsis, aspiration and pneumonia. Little is known
about the relation between the setting where the syndrome developed and outcomes in ARDS patients.
Methods: This is a 1-year prospective observational study conducted at a tertiary referred hospital. ARDS was
defined by the Berlin criteria. Community-acquired ARDS, hospital-acquired ARDS and intensive care unit
(ICU)-acquired ARDS were defined as ARDS occurring within 48 hours of hospital or ICU admission, more than
48 hours after hospital admission and ICU admission. The primary and secondary outcomes were short- and
long- term mortality rates and ventilator-free and ICU-free days.
Results: Of the 3002 patients screened, 296 patients had a diagnosis of ARDS, including 70 (23.7 %) with
community-acquired ARDS, 83 (28 %) with hospital-acquired ARDS, and 143 (48.3 %) with ICU-acquired ARDS. The
overall ICU mortality rate was not significantly different in mild, moderate and severe ARDS (50 %, 50 % and 56 %,
p = 0.25). The baseline characteristics were similar other than lower rate of liver disease and metastatic malignancy
in community-acquired ARDS than in hospital-acquired and ICU-acquired ARDS. A multiple logistic regression
analysis indicated that age, sequential organ function assessment score and community-acquired ARDS were
independently associated with hospital mortality. For community-acquired, hospital-acquired and ICU-acquired
ARDS, ICU mortality rates were 37 % 61 % and 52 %; hospital mortality rates were 49 %, 74 % and 68 %. The ICU
and hospital mortality rates of community-acquired ARDS were significantly lower than hospital-acquired and
ICU-acquired ARDS (p = 0.001 and p = 0.001). The number of ventilator-free days was significantly lower in ICU-acquired
ARDS than in community-acquired and hospital-acquired ARDS (11 ± 9, 16 ± 9, and 14 ± 10 days, p = 0.001). The number
of ICU-free days was significantly higher in community-acquired ARDS than in hospital-acquired and ICU-acquired ARDS
(8 ± 10, 4 ± 8, and 3 ± 6 days, p = 0.001).
Conclusions: Community-acquired ARDS have lower short- and long-term mortality rates than hospital-acquired
or ICU-acquired ARDS.
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Introduction
Acute respiratory distress syndrome (ARDS) is a signifi-
cantly heterogeneous syndrome that involves many
different groups of patients that may influence outcomes
[1–3]. The Berlin definition classifies ARDS into mild,
moderate, and severe by hypoxemia severity, using the
PaO2/FiO2 ratio [4]. The predictive validity for mortality
according to the Berlin definition has not been validated
in recent studies [5–7]. The absolute predictive value is
modest and suggests that some factors other than
hypoxemia need to be investigated [8].
Differences in mortality rates have been demonstrated
for patients with community-acquired pneumonia and
hospital-acquired pneumonia [9]. For ARDS patients, a
majority of patients developed acute lung injury (ALI)/
ARDS within the first five days, especially 48–72 h after
admission [10]. A retrospective cohort study showed a
trend of decreasing prevalence in hospital-acquired and
intensive care unit (ICU)-acquired ARDS patients over
an eight-year period [11]. A prospective, multi-center,
observational study revealed that late-onset ALI/ARDS
patients had longer ICU and hospital stays than early-
onset ALI/ARDS patients, but the mortality rate was not
significantly different [12].
Little is known of the characteristics of patients in differ-
ent ARDS subgroups according to the setting where the
syndrome developed. The aim of this study is to investigate
the outcomes of community-acquired, hospital-acquired
and ICU-acquired ARDS patients. It has not been studied
in the literature before and is a newly thought of patient
population for ARDS. In addition to the severity of ARDS,
the different categories may be an important factor for out-
comes and, therefore, for clinical trials assessing the effects
of potential interventions.
Methods
Study design and study population
A prospective observational study was conducted from
September 2012 to August 2013 at Chang Gung Memorial
Hospital, a tertiary care referral center with 3,700 ward
beds and 278 adult ICU beds. These 278 adult ICU beds
are distributed in 17 ICUs (nine medical ICUs, seven
surgical ICUs, one burn ICU). All of the admitted patients
with invasive mechanical ventilation were screened for
eligibility by the Hospital Information System. Eligible
patients were further evaluated when both chest-X-ray
and PaO2/FiO2 ratio criteria were present concurrently.
Patients were included if they met the criteria of the Berlin
definition of ARDS and those with ARDS were further
reviewed by a second independent investigator (LC Chiu)
blind to the previous screening results. Differences were
resolved by discussion between the two senior intensive
care physicians (KC Kao and HC Hu).
Patients were excluded if they were younger than
18 years old or had been admitted to another hospital
and referred for admission. The Chang Gung Memorial
Hospital’s Institutional Review Board Ethics Committee
approved the study protocol and informed consent was
waived (CGMH IRB No.102-1729B).
Definitions
The Berlin definition of ARDS includes: (1) onset within
one week of a known clinical insult or new or worsening
respiratory symptoms; (2) bilateral opacities not fully
explained by effusions, lobar/lung collapse, or nodules;
(3) respiratory failure not fully explained by cardiac fail-
ure or fluid overload and needs objective assessment
(e.g., echocardiography) to exclude hydrostatic edema if
no risk factor is present; and (4) PaO2/FiO2 ratio
≤300 mm Hg with positive-end expiratory pressure
(PEEP) or continuous positive airway pressure (CPAP) ≥
5 cm H2O [4].
According to the setting where the ARDS syndrome de-
veloped, we categorized ARDS patients into community-
acquired, hospital-acquired and ICU-acquired ARDS.
Community-acquired ARDS was defined as ARDS occur-
ring upon admission or within 48 hours of hospital or
ICU admission. Hospital-acquired ARDS was defined as
ARDS occurring > 48 hours after hospital admission. ICU-
acquired ARDS was defined as ARDS occurring > 48 hours
after ICU admission (11). All the ARDS patients had the
known clinical insults or worsening respiratory symptoms
within one week.
General management
It was recommended that patients be ventilated with
protective ventilation using low tidal volume 4–8 mL/kg
of predicted body weight plus moderate to high levels of
PEEP for volume-controlled or pressure-controlled
ventilation [13]. The predicted body weight of male
patients was calculated as equal to 50 + 0.91 (height in
centimeters - 152.4) and of female patients as equal to
45.5 + 0.91 (height in centimeters - 152.4). Ventilation
was monitored by arterial blood gas measurements, with
ventilator settings changed as needed. Pulse oximetry
(SpO2) was used to monitor oxygenation and the FiO2
was adjusted to maintain SpO2 > 90 % or PaO2 > 60 mm
Hg and to avoid raising the peak inspiratory pressure >
35 cm H2O.
The general medical management including fluid
replacement, the use of antibiotics, corticosteroids in
some selected patients and vasopressor agents, sedation
with infusions of midazolam and paralysis with infusions
of cisatracurium was directed by the intensivists-in-
charge. The patients had a peripheral arterial line and
PiCCO plus monitoring (version 5.2.2; Pulsion Medical
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System AG, Munich, Germany) for hemodynamic moni-
toring if indicated.
Data collection
Demographics and baseline clinical information were
collected on enrollment. Data on patient outcome
90 days after inclusion were tracked. The following data
were recorded upon ICU admission: date of hospital and
ICU admission, age, gender, body weight and height,
underlying disease, and risk factors of ARDS. The mech-
anical ventilator settings (i.e., artery blood gas, tidal vol-
ume, lowest PaO2/FiO2 ratio with the highest PEEP, and
peak airway pressure) were recorded during mechanical
ventilation at the time of ARDS diagnosis. The Charlson
comorbidity index (CCI) [14], Acute Physiology and
Chronic Health Evaluation (APACHE) II score [15],
Sequential Organ Failure Assessment (SOFA) score [16],
Multiple Organ Dysfunction (MOD) score [17], and
Lung Injury score (LIS) [18] were recorded on the day of
inclusion and on days 3, 7, and 14 after inclusion.
Regarding the definitions of liver disease in CCI, mild
liver disease was chronic hepatitis or cirrhosis without
portal hypertension. Moderate and severe liver diseases
were cirrhosis combined with portal hypertension with-
out and with history of varices bleeding [14].
The primary outcome was mortality (in ICU, at 28 days,
at 60 days, and at 90 days, in hospital) and the secondary
outcomes were ICU-free days and ventilator-free days.
The number of ventilator-free days or ICU-free days was
the mean number of days from day 1 to day 28 on which
the patient had been breathing without assistance for at
least 48 consecutive hours or which the patient had been
transferred to ward from ICU. Patients who did not
survive to 28 days were assigned zero ventilator-free days
and zero ICU-free days.
Statistical analysis
Descriptive statistics were expressed as mean ± SD
(standard deviation). All variables were tested for normal
distributions using the Kolmogorov-Smirnov test. Student
t test was used to compare the means of continuous vari-
ables with normal distribution and the Mann–Whitney U
test for the rest. Categorical data were compared using the
chi square test. Risk factors for hospital mortality were
analyzed using univariate analysis, and the variables statis-
tically significant (p < 0.05) in the univariate analysis were
included in the multivariate analysis by applying a mul-
tiple logistic regression based on backward elimination of
data. The Hosmer-Lemeshow goodness-of-fit test was
used for calibration when evaluating the number of ob-
served and predicted deaths in risk groups for the death
probabilities. Cumulative survival curves as a function of
time were generated using the Kaplan-Meier approach
and compared using the log-rank test. All statistical tests
were two-tailed and p < 0.05 was considered statistically
significant. All statistical analyses were performed using
the SPSS (SPSS for Windows, SPSS Inc., Chicago, IL,
USA) statistical package.
Results
During the study period, 3,002 admitted patients with
invasive mechanical ventilation were screened (Fig. 1).
Fig. 1 Flow chart for patients’ enrollment in the study. IMV invasive mechanical ventilation, ARDS acute respiratory distress syndrome
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After excluding 2,664 patients who did not meet the
ARDS criteria and 42 ARDS patients referred from other
hospitals, 296 ARDS patients were included for analysis.
Of these 296 ARDS patients, 24 patients underwent
adjudication to have a definitive diagnosis of ARDS. The
most common was ICU-acquired ARDS at 48.3 %,
followed by hospital-acquired ARDS at 28 %, and
community-acquired ARDS at23.7 %.
Demographic and clinical characteristics of the study
patients revealed a male predominance (Table 1). The
average lung injury score was 2.9 ± 0.5. The mean PaO2/
FiO2 ratio was 129.1 ± 70.0 mm Hg. Following the Berlin
definition, 51 patients (17.2 %) were classified as mild
ARDS, 109 (36.8 %) as moderate ARDS, and 136 (46 %)
as severe ARDS. The ICU mortality rates in mild, mod-
erate, and severe ARDS patients were 50 %, 50 %, and
56 %, respectively, without a significant difference
between the three groups (p = 0.25). Of the primary lung
injury causes, pneumonia was the most common (n = 141),
followed by aspiration (n = 52), inhalation injury (n = 4),
and lung contusion (n = 2). Of the secondary lung injury
causes, sepsis was the most common (n = 81), followed by
major surgery (n = 8), acute pancreatitis (n = 6), and mul-
tiple transfusions with red blood cells (RBCs) (n = 2).
Pressure-controlled mode was applied in 278 patients
(93.9 %) and volume-controlled mode in 18 patients
(6.1 %).
The demographic and clinical characteristics of different
types of ARDS patients are shown in Table 1. Comparison
among the three diagnosis groups revealed no statistically
significant differences regarding age, gender, body weight,
severity, causes, ventilation, oxygenation, and initial mech-
anical ventilation setting. Of the community-acquired
ARDS patients, nine (12.9 %) were classified as mild
ARDS, 24 (34.3 %) as moderate ARDS, and 37 (52.9 %) as
severe ARDS. Of the hospital-acquired ARDS patients, 14
(16.9 %) were classified as mild, 31 (37.3 %) as moderate,
and 38 (45.8 %) as severe ARDS. Of the ICU-acquired
ARDS patients, 28 (19.6 %) were classified as mild, 54
(37.8 %) as moderate, and 61 (42.7 %) as severe ARDS.
The distribution of severity in these three groups was not
statistically significant (p = 0.65).
Prone position was applied to three patients with
community-acquired ARDS, five with hospital-acquired
ARDS, and three with ICU-acquired ARDS. Venovenous
extra-corporeal membrane oxygenation was used in
three patients with community-acquired ARDS, four
with hospital-acquired ARDS, and three with ICU-
acquired ARDS.
In terms of outcome parameters, community-acquired
ARDS patients had the lowest ICU mortality rate
compared to hospital-acquired and ICU-acquired ARDS
patients (37 %, 61 %, and 52 %, respectively, p = 0.001)
(Table 2). The 28-day, 60-day, 90-day, and hospital
mortality rates had the same trends. The overall survival
rate in community-acquired ARDS was significantly
higher than hospital-acquired and ICU-acquired ARDS
(p = 0.0024) (Fig. 2). The number of ventilator-free days
was significantly lower in the ICU-acquired ARDS
patients than in the community-acquired and hospital-
acquired ARDS patients (11 ± 9, 16 ± 9, and 14 ± 10 days,
respectively, p = 0.001). The number of ICU-free days
was significantly higher in the community-acquired
ARDS patients than in the hospital-acquired or ICU-
acquired ARDS patients (8 ± 10, 4 ± 8, and 3 ± 6 days,
respectively, p = 0.001). Univariate analysis and multi-
variate logistic regression analysis were used to identify
variables for hospital mortality that had significant prog-
nostic value (Table 3). Identification of age [odds ra-
tio 1.038, 95 % confidence interval (CI) 1.02-1.056,
p < 0.001], SOFA score (odds ratio 1.287, 95 % CI 1.184-
1.399, p < 0.001) and community-acquired ARDS (odds
ratio 0.463, 95 % CI 0.250-0.855, p = 0.014) were signifi-
cantly and independently associated with hospital mortal-
ity. Regression coefficients of these variables were
used to calculate a natural logarithm of the odds
(logit) of the probability of death (p), as follows: logit
(p) =−5.206 + (0.038 × age) + (0.252 × SOFA score) + (1.029 ×
hospital-acquired ARDS) + (0.732 × ICU-acquired ARDS).
The CCI was lower in community-acquired ARDS
patients than hospital-acquired and ICU-acquired ARDS
patients but the difference was not significant (2.83 ± 2.2,
3.63 ± 2.8, and 3.56 ± 2.2, respectively, p = 0.068) (Table 1).
Regarding the components of CCI, community-acquired
ARDS patients had less moderate to severe liver disease
than hospital-acquired and ICU-acquired ARDS patients
(0 %, 34 %, and 66 %, respectively, p = 0.000).
Discussion
This one-year prospective observational study found that
community-acquired ARDS patients had better short-
and long-term mortality rates than hospital-acquired
and ICU-acquired ARDS patients. Community-acquired
ARDS patients had less underlying moderate to severe
liver disease than hospital-acquired and ICU-acquired
ARDS patients. The community-acquired ARDS patients
had more ICU-free days than hospital-acquired or ICU-
acquired ARDS patients and the ICU-acquired ARDS
patients had fewer ventilator-free days than community-
acquired or hospital-acquired ARDS patients.
The incidence of ARDS varies widely. Differences in
demographics, healthcare systems, and definitions may
account for different incidences of ARDS in different
areas or countries. In adult population-based studies, the
incidence of ARDS by the American-European consen-
sus (AECC) definition ranged from 5–7.2 cases/100,000/
year in Europe to 33.8/100,000/year in USA [11, 19–21].
For ICU patients, the reported incidence of ALI/ARDS
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Table 1 Demographics and clinical characteristics of patients with different types of ARDS at the time of ARDS diagnosis
Characteristics Total ARDS Community-acquired ARDS Hospital-acquired ARDS ICU-acquired ARDS p
(n = 296) (n = 70) (n = 83) (n = 143)
Age (years) 63.0 ± 16.5 62.8 ± 19.9 62.3 ± 16.0 63.5 ± 15.2 0.855
Gender (male/female) 198/98 47/23 50/33 101/42 0.278
BMI (kg/m2) 23.6 ± 4.2 23.9 ± 3.9 23.6 ± 3.7 23.5 ± 4.6 0.811
PBW 57 ± 10 56.8 ± 8.0 56.2 ± 10.5 57.6 ± 10.6 0.580
CCI 3.4 ± 2.4 2.83 ± 2.2 3.63 ± 2.8 3.56 ± 2.2 0.068
APACHE II score 25.1 ± 6.9 26.1 ± 6.6 24.5 ± 6.9 25.0 ± 7.2 0.339
SOFA score 11.5 ± 3.8 10.7 ± 3.5 11.7 ± 4.0 11.8 ± 3.9 0.107
MOD score 9.8 ± 3.4 9.3 ± 2.9 9.9 ± 3.6 10.0 ± 3.6 0.300
Lung injury score 2.9 ± 0.5 3.1 ± 0.4 2.9 ± 0.5 3.0 ± 0.5 0.249
Tidal volume (ml/PBW) 8.4 ± 2.0 8.1 ± 1.7 8.7 ± 1.9 8.3 ± 2.1 0.241
PEEP (cm H2O) 10.2 ± 2.2 10.1 ± 2.0 9.8 ± 1.9 10.5 ± 2.5 0.078
Peak Paw (cm H2O) 29.8 ± 5.9 30.0 ± 5.2 29.6 ± 5.3 29.8 ± 6.5 0.918
pH 7.35 ± 0.11 7.33 ± 0.11 7.37 ± 0.12 7.35 ± 0.11 0.059
PaCO2 (mm Hg) 45.0 ± 17.3 44.9 ± 13.7 41.4 ± 14.9 47.2 ± 19.8 0.053
FiO2 0.8 ± 0.2 0.81 ± 0.19 0.79 ± 0.22 0.77 ± 0.23 0.082
PaO2/FiO2 (mm Hg) 129.1 ± 70.0 115.0 ± 66.4 132.3 ± 68.1 133.8 ± 72.3
Severity of ARDS
Mild 51(17.2 %) 9(12.9 %) 14(16.9 %) 28(19.6 %) 0.3383
Moderate 109(36.8 %) 24(34.3 %) 31(37.3 %) 54(37.8 %) 0.7677
Severe 136(46.0 %) 37(52.9 %) 38(45.8 %) 61(42.7 %) 0.6242
Cause of ARDS
Pneumonia 141 34(48.6 %) 48(57.8 %) 59(41.3 %) 0.055
Sepsis 81 18(25.7 %) 21(25.3 %) 42(29.4 %) 0.755
Aspiration 52 11(15.7 %) 19(22.9 %) 22(15.9 %) 0.323
Major surgery 8 2(2.9 %) 3(3.6 %) 3(2.1 %) 0.733
Acute pancreatitis 6 1(1.4 %) 1(1.2 %) 4(2.8 %) 0.872
Others 8 2(2.9 %) 2(2.4 %) 4(2.8 %) 1.000
Components of CCI
Myocardial infarct 10 1(1.4 %) 3(3.6 %) 6(4.2 %) 0.570
CHF 29 8(11.4 %) 9(10.8 %) 12(8.4 %) 0.729
Peripheral vascular disease 11 4(5.7 %) 2(2.4 %) 5(3.5 %) 0.550
Cerebrovascular disease 91 25(35.7 %) 24(28.9 %) 42(29.4 %) 0.562
Dementia 6 3(4.3 %) 1(1.2 %) 2(1.4 %) 0.306
Chronic pulmonary disease 31 11(15.7 %) 7(8.4 %) 13(9.1 %) 0.258
Connective tissue disease 1 0(0 %) 1(1.2 %) 0(0 %) 0.276
Ulcer disease 47 6(8.6 %) 13(15.7 %) 28(19.6 %) 0.118
Mild liver disease 12 1(1.4 %) 3(3.6 %) 8(5.6 %) 0.341
Diabetes without end organ damage 80 21(30 %) 17(20.5 %) 42(29.4 %) 0.284
Hemiplegia or paraplegia 16 5(7.1 %) 3(3.6 %) 8(5.6 %) 0.542
Moderate to severe renal disease 88 25(35.7 %) 18(21.7 %) 45(31.5 %) 0.137
Diabetes with end organ damage 3 0(0.0 %) 1(1.2 %) 2(1.4 %) 0.472
Any tumor without metastasis 44 8(11.4 %) 15(18.1 % ) 21(14.7 %) 0.514
Leukemia 2 0(0 %) 0(0 %) 2(1.4 %) 0.341
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by the AECC definition was 7.1 % in Europe and 7.7 %
in Argentina [22, 23]. A cross-sectional study demon-
strated that patients with ARDS correspond to about 5 %
of hospitalized, mechanically-ventilated patients [24]. A
recent study in Brazil revealed that the prevalence of
ARDS by the Berlin definition in ICU patients was 1.8 %
[6]. In this study, the incidence of ICU-acquired ARDS by
the Berlin definition in mechanically-ventilated patients
was 5.4 % (143/2,664), accounting for nearly 50 % of all
three types of ARDS patients. Thus, the prevention of
ARDS in ICU patients is an important issue. It is possible
that a broad application of lung protective ventilation, bet-
ter infection and aspiration control, and fewer blood
transfusions can decrease the prevalence of ICU-acquired
ARDS.
For critically-ill patients, the lead time of events is an
important prognostic factor, but the correlation between
the time of disease onset and outcomes is controversial.
Late-onset septic shock (>24 h after ICU admission) was
associated with a higher mortality rate but not signifi-
cant in patients with early-onset septic shock (<24 h
after ICU admission) (88 % vs. 63 %, p = 0.071) [25].
There was no difference in the mortality rates of patients
with sepsis on ICU admission, those who developed
sepsis within 48 h after ICU admission, and those who
developed sepsis > 48 h after ICU admission (27 % vs.
20 % vs. 28 %, p = 0.526) in the Sepsis Occurrence in
Acutely Ill Patients (SOAP) study [26]. However, in a
multivariate analysis of patients with shock from the
SOAP database, late-onset (>48 h after ICU admission)
shock was an independent predictor of higher ICU
mortality (odds ratio, 2.6; 95 % CI, 1.6-4.3; p < 0.001)
[27]. For renal failure, later onset was associated with
worse prognosis than early onset in ICU patients with
mechanical ventilation [28–30]. For post-traumatic
ARDS patients, there was no difference in mortality
rates between the early (within 48 h of hospital admis-
sion) and late (>48 h of hospital admission) groups
(27 % vs. 21 %) [31]. Sub-analysis of the SOAP database
demonstrated no significant difference in ICU mortality
rates between early- and late-onset ARDS (45.7 % vs.
35.5 %) [12].
The overall ICU mortality rate was not significantly
different in mild, moderate, and severe ARDS (50 %,
50 %, and 56 %, p = 0.25) in this study. The previous
study in ARDS patients found that the presence of
serious comorbidities, such as acquired immune defi-
ciency syndrome, metastatic cancer, immunocomprom-
ised, liver cirrhosis, and hepatic failure, almost tripled
the mortality rate after hospital discharge compared to
Table 1 Demographics and clinical characteristics of patients with different types of ARDS at the time of ARDS diagnosis (Continued)
Lymphoma 4 0(0 %) 1(1.2 %) 3(2.1 %) 0.616
Moderate to severe liver disease 47 0(0.0 %) 16(19.3 %) 31(21.7 %) 0.000*
Metastatic solid tumor 41 5(7.1 %) 17(20.5 %) 19(13.3 %) 0.057
AIDS 2 2(2.9 %) 0(0.0 %) 0(0.0 %) 0.039*
Abbreviations: ARDS acute respiratory distress syndrome, ICU intensive care unit, BMI body mass index, PBW predict body weight, CCI Charlson comorbidity index,
APACHE acute physical and chronic health evaluation, SOFA sequential organ function assessment, MOD multiple organ dysfunction, Paw airway pressure, PaO2/
FiO2 alveolar oxygen pressure/fraction of inspiratory oxygen, PEEP positive end expiratory pressure, CHF congestive heart failure, AIDS acquired
immunodeficiency syndrome
All values are expressed as No. of patients (%) or mean ± SD
*p < 0.05: Community-acquired ARDS vs. hospital-acquired ARDS vs. ICU-acquired ARDS
Table 2 Outcomes in different types ARDS patients
Outcomes Community-acquired ARDS Hospital-acquired ARDS ICU-acquired ARDS p
(n = 70) (n = 83) (n = 143)
Mortality –no.(% [95 % CI])
In ICU 26 (37*[26–49]) 51 (61[51–72]) 75 (52[44–61]) 0.001
At 28-day 31 (44*[33–56]) 56 (68[57–78]) 89 (62[54–70]) 0.012
At 60-day 33 (47*[35–59]) 58 (70[60–80]) 92 (64[56–72]) 0.001
At 90-day 33 (47*[35–59]) 59 (71[61–81]) 97 (68[60–76]) 0.001
In hospital 34 (49*[37–60]) 61 (74[64–83]) 97 (68[60–76]) 0.001
No. of ventilator-free days, days 1 to 28 16 ± 9 14 ± 10 11 ± 9† 0.001
No. of ICU-free days, Days 1 to 28 8 ± 10* 4 ± 8 3 ± 6 0.001
Abbreviations: ARDS acute respiratory distress syndrome, MV mechanical ventilation, LOS length of stay, ICU intensive care unit
All values are expressed as No of patients (% [95 % CI]) or mean ± SD
*p < 0.05: Community-acquired ARDS vs. hospital-acquired ARDS and vs ICU-acquired ARDS
†p < 0.05: ICU-acquired ARDS vs. Community-acquired ARDS and vs Hospital-acquired ARDS
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those with none [32]. The present study revealed that
community-acquired ARDS patients had a significantly
lower ICU mortality rate than hospital-acquired and
ICU-acquired ARDS patients. Further analysis of the co-
morbidities showed that moderate to severe liver disease
is less prevalent in the community-acquired ARDS pa-
tients than hospital-acquired and ICU-acquired ARDS
patients (0 %, 19.3 %, and 21.7 %, p = 0.000). More pa-
tients with severe liver dysfunction may contribute to
the high mortality rates in hospital-acquired and ICU-
acquired ARDS patients than community-acquired
ARDS patients. The patients with underlying severe
chronic liver disease were always excluded in the most
randomized controlled trials of ARDSnet [13, 33–37]. It
is difficult to determine whether comorbidities with ad-
vanced liver disease or the severity of ARDS most influ-
ence the survival outcomes. The comorbidities could
affect survival in ARDS patients and this needs further
investigation.
For ARDS patients, there are many conditions associ-
ated with mortality. ARDS is a syndrome that is not, by
itself, a cause of mortality but rather accompanies other
disease processes. The cause of ARDS such as pneumo-
nia, aspiration or sepsis, severity of ARDS, underlying
comorbidities, and cause of death may relate to the mor-
tality. In this study, the cause and severity of ARDS were
not significantly different between the three categories.
In addition to moderate to severe liver disease, more
patients had underlying metastatic solid tumors in
hospital-acquired and ICU-acquired ARDS than
community-acquired ARDS. Given the poor prognosis
of cancer patients with ARDS, it may explain, at least in
part, the poor outcome in patients with hospital-
acquired and ICU-acquired ARDS compared to
community-acquired ARDS. Furthermore, it is possible
that hospital-acquired and ICU-acquired ARDS may
have worse prognosis due to the presence of hospital
exposures that are known to increase the risk for
Fig. 2 Kaplan-Meier survival curve of community-acquired ARDS,
hospital-acquired ARDS, and ICU-acquired ARDS. ARDS acute respira-
tory distress syndrome, ARDS acute respiratory distress syndrome,
ICU intensive care unit
Table 3 Univariate and multivariate logistic regression analysis of clinical variables associated with hospital mortality in ARDS
patients
Parameter Beta coefficient Standard error Odds ratio (95 % CI) p value
Univariate logistic regression
Age 0.024 0.008 1.024 (1.010-1.040) 0.001*
Female gender −0.148 0.257 0.862 (0.522-1.426) 0.564
APACHEI II score 0.066 0.019 1.068 (1.029-1.108) <0.001*
SOFA score 0.223 0.039 1.249 (1.157-1.349) <0.001*
MOD score 0.175 0.041 1.191 (1.099-1.291) <0.001*
PaO2/FiO2 −0.001 0.002 0.999 (0.996-1.003) 0.683
CCI 0.161 0.055 1.174(1.055-1.307) 0.003*
Moderate to severe liver disease 0.553 0.359 1.739 (0.860-3.516) 0.124
Metastatic solid tumor 0.929 0.415 2.532 (1.124-5.708) 0.025*
Community-acquired ARDS −0.879 0.279 0.415(0.240-0.718) 0.002*
Multivariate logistic regression
Age 0.037 0.009 1.038 (1.020-1.056) <0.001*
SOFA score 0.252 0.043 1.287 (1.184-1.399) <0.001*
Metastatic solid tumor 0.751 0.448 2.120 (0.881-5.099) 0.093
Community-acquired ARDS −0.771 0.313 0.463 (0.250-0.855) 0.014*
Constant −4.400 0.814 0.012 <0.001*
Abbreviations: ARDS acute respiratory distress syndrome, CI confidence interval, APACHE acute physical and chronic health evaluation, SOFA sequential organ
function assessment, MOD multiple organ dysfunction, PaO2/FiO2 alveolar oxygen pressure/fraction of inspiratory oxygen, CCI Charlson comorbidity index
*p value < 0.05
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hospital–acquired ARDS, such as aspiration, non-
protective ventilation, inadequate antibiotics and source
control, surgical or medical errors, and too much fluid
and transfusion [38].
In this study, ICU-acquired ARDS patients had fewer
ventilator-free days than the other two types of ARDS
patients and had fewer ICU-free days than community-
acquired patients (Table 2). These patients had already
been treated in the ICU for more than two days due to
previous insults or poor conditions before ARDS oc-
curred. After suffering from ARDS, the longer ventilator
use and ICU stay might be due to the fragile characteris-
tics of these ICU patients. The medical cost in the ICU
would be effectively reduced if we could recognize ARDS
early and prevent its occurrence in these ICU patients.
Although some randomized controlled trials have
reported improvements in mortality, the current overall
hospital mortality is about 40-50 % in most series of
ARDS patients [20, 39]. The different reported mortality
rates in ARDS patients may be due to differences in
patient selection, associated underlying diseases, predis-
posing or risk factors for ARDS, severity of hypoxemia,
and setting of mechanical ventilation. For example,
trauma-induced ARDS had favorable prognosis, with ap-
proximately 10 % 60-day mortality rate [40, 41]. How-
ever, the hospital mortality rate was higher at 68.8 % in
cancer patients with ARDS [42]. In the present observa-
tional cohort study, the ICU mortality varies from 37 %
to 61 % in three different types of ARDS. Other than the
presence of malignancies and a high prevalence of liver
failure, one of the reasons for the high mortality rate
could be the use of high tidal volume (>9 ml/kg PBW)
in a substantial proportion of this cohort (Table 1). As a
consequence of high mortality and considerable variabil-
ity in outcomes in ARDS patients, classification of
phenotype for mortality is essential for predicting prog-
nosis, guiding clinical decision-making, and designing
prospective randomized controlled trials.
There are some limitations in this study. First, mis-
diagnosis of ARDS is a potential limitation derived from
reliance on available diagnostic criteria. To diminish this
possible bias, the diagnosis of ARDS was based on estab-
lished criteria and the accuracy of diagnosis was verified
through a separate case review by three independent
intensive care physicians. Second, the study design lim-
ited patients to those who required invasive mechanical
ventilation to identify those most at risk of subsequent
mortality, thereby losing patients who met the criteria
for ARDS but only received non-invasive ventilation.
Third, a low tidal volume strategy was not fully applied
in all of the ARDS patients and ventilator-induced lung
injury might have contributed to mortality. However,
this would have equally exerted an impact on all three
types of ARDS patients and should not influence the
results. Fourth, different management strategies may
alter the ARDS-related outcomes, but this study does
not identify the correlation between management strat-
egies and mortality. Lastly, perhaps the main limitation
is the single-center nature of the study population. Al-
though strengthened by the prospective, cohort, and ob-
servational design, this may limit the generalization of
the study results and warrant external validation.
Conclusions
In this study, the overall ICU mortality rate was not
significantly different in mild, moderate, and severe
ARDS. According to the timing of onset and admission
source, three types of patients with ARDS are classified
as community-acquired, hospital-acquired, and ICU-
acquired ARDS. The most common is ICU-acquired
ARDS with 48.3 %, followed by hospital-acquired ARDS
with 28 %, and community-acquired ARDS with 23.7 %.
Community-acquired ARDS patients have better short-
and long-term mortality rates than hospital-acquired or
ICU-acquired ARDS patients. Underlying advanced liver
disease may contribute to the different outcomes be-
tween these three groups. Patients with ICU-acquired
ARDS have lower numbers of ventilator-free days and
ICU-free days than those with community-acquired or
hospital-acquired ARDS. These data provide relevant in-
formation on ARDS patients for evaluating individual
outcomes and designing clinical trials.
Key messages
 In this prospective study, according to the timing of
onset and admission source, the most commonly
occurring ARDS is ICU-acquired ARDS with 48.3 %,
followed by hospital-acquired ARDS with 28 %, and
community-acquired ARDS with 23.7 %.
 Community-acquired ARDS patients have better
short- and long-term mortality rates than hospital-
acquired or ICU-acquired ARDS patients.
 ICU-acquired ARDS patients have lower numbers of
ventilator-free days and ICU-free days than those
with community-acquired or hospital-acquired
ARDS.
 In terms of different outcomes, classification
according to the setting where the ARDS developed
may be considered in designing clinical therapeutic
trials in the future.
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